↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Gelderblom H.) srt2:(2005-2009)"

Search: WFRF:(Gelderblom H.) > (2005-2009)

Result 1-5 of 5

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Hooker, Andrew C, et al. (author) Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function : incorporating cytochrome P4503A activity measurements 2008 In: Clinical Pharmacology and Therapeutics. - : Springer Science and Business Media LLC. - 0009-9236 .- 1532-6535. ; 84:1, s. 111-118 Journal article (peer-reviewed)abstract The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m(2) was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83% of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47% of variation; covariates accounted for only 23% of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.
2.	Humblet, Y, et al. (author) Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study 2007 In: EJC SUPPLEMENTS. - 1359-6349. ; 5:4, s. 240-240 Conference paper (other academic/artistic)
3.	Tejpar, S, et al. (author) Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. 2006 In: JOURNAL OF CLINICAL ONCOLOGY. - 0732-183X. ; 24:18, s. 159S-159S Conference paper (other academic/artistic)
4.	Van, CE, et al. (author) Cetuiximab dose-escalation in mcrc patients with no or slight skin reactions on standard treatment (everest) 2007 In: ANNALS OF ONCOLOGY. - 0923-7534. ; 18, s. VII22-VII22 Conference paper (other academic/artistic)
5.	Van Cutsem, E, et al. (author) Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study 2006 In: ANNALS OF ONCOLOGY. - 0923-7534. ; 17 Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-5 of 5

Refine your search

Type of publication: conference paper (4); journal article (1)

Type of content: other academic/artistic (4); peer-reviewed (1)

Author/Editor: Gelderblom, H (5); Glimelius, B (4); Peeters, M (4); Ciardiello, F (4); Humblet, Y (4); Viret, F (4); show more...; Van Cutsem, E (3); Gallerani, E (3); Kisker, O (3); Vermorken, JB (2); Vermorken, J (2); Weber, J. (1); Hooker, Andrew C. (1); Karlsson, Mats O. (1); Carducci, M A (1); Weber, D (1); Verweij, J. (1); Ten Tije, A J (1); Garrett-Mayer, E (1); McGuire, W P (1); Baker, S D (1); Tejpar, S (1); Van, CE (1); show less...

University: Karolinska Institutet (4); Uppsala University (1)

Language: English (5)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view